Literature DB >> 33174323

Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.

Xiaying Chen1,2, Zuyi Yang1,2, Jiao Feng1,2, Ting Duan1,2, Ting Pan1,2, Lili Yan1,2, Ting Jin1,2, Yu Xiang1,2, Mingming Zhang1,2, Peng Chen1,2, Wengang Wang1,2, Ruonan Zhang1,2, Bi Chen1,2, Liping Zhao1,2, Tian Xie1,2, Xinbing Sui1,2.   

Abstract

PURPOSE: To evaluate the relationship between the DNA mismatch repair (MMR) status and histone lysine-specific demethylase 6A (KDM6A) on the prognosis of colorectal cancer (CRC).
METHODS: About 594 patients with CRC from The Cancer Genome Atlas (TCGA) were enrolled in this retrospective study. Subsequently, a series of different classification tests for MMR status, cancer types, and target gene expression was conducted.
RESULTS: After filtering out the KDMs group of genes, we selected KDM6A as the target gene. A significant difference in the performance of KDM6A in tumor and normal tissues were confirmed. Our results showed a lower KDM6A expression, lower KDM6A exon expression, and higher KDM6A DNA methylation than their corresponding normal tissues in colon adenocarcinoma (COAD). Notably, the main MMR genes were highly expressed in tumor tissues than normal tissues both in COAD and rectum adenocarcinoma (READ). Moreover, proficient DNA mismatch repair (pMMR) was found to be an important poor prognostic factor in COAD (p = 0.0064) and the low KDM6A expression was an important factor for poor prognosis in READ (p = 0.0217). Based on these results, we consequently relate MMR status with KDM6A expression in predicting the prognosis of patients with CRC. Moreover, patients with pMMR exhibited a low KDM6A expression in COAD (p = 0.0250). Samples were divided into two groups based on the KDM6A expression. Interestingly, the group with low KDM6A expression showed no difference between pMMR and deficient DNA mismatch repair (dMMR) in prognosis, whereas the group with high KDM6A expression was closely related to MMR status in OS (p = 0.0082). Besides, COAD patients with high KDM6A expression and pMMR status had poor OS (p = 0.0082).
CONCLUSIONS: The KDM6A/MMR classification-based subtypes of low KDM6A expression/READ, high KDM6A expression/pMMR, and COAD/pMMR were associated with poor prognosis. This classification can be a novel prognostic approach in CRC.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33174323      PMCID: PMC7826484          DOI: 10.1002/cam4.3602

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  30 in total

Review 1.  Four molecular subtypes of colorectal cancer and their precursor lesions.

Authors:  Gyeong Hoon Kang
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

2.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.

Authors:  M F Kane; M Loda; G M Gaida; J Lipman; R Mishra; H Goldman; J M Jessup; R Kolodner
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

3.  Routine Molecular Analysis for Lynch Syndrome Among Adenomas or Colorectal Cancer Within a National Screening Program.

Authors:  Anne Goverde; Anja Wagner; Marco J Bruno; Robert M W Hofstra; Michael Doukas; Marcel M van der Weiden; Hendrikus J Dubbink; Winand N M Dinjens; Manon C W Spaander
Journal:  Gastroenterology       Date:  2018-07-29       Impact factor: 22.682

4.  Protocadherin γ-A7 is down-regulated in colorectal cancer and associated with the prognosis in patients with wild-type KRAS.

Authors:  Yingdi Liu; Kangsheng Peng; Ruting Xie; Jiayi Zheng; Jing Guo; Rong Wei; Huiqiong Yang; Chunmiao Cai; Qing Wei
Journal:  Hum Pathol       Date:  2018-08-16       Impact factor: 3.466

Review 5.  Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer.

Authors:  James J Lee; Edward Chu
Journal:  Clin Colorectal Cancer       Date:  2018-06-21       Impact factor: 4.481

6.  Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination.

Authors:  Wei Zhao; Qingtian Li; Stephen Ayers; Yifeng Gu; Zhong Shi; Qingyuan Zhu; Yidong Chen; Helen Y Wang; Rong-Fu Wang
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

7.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.

Authors:  J G Herman; A Umar; K Polyak; J R Graff; N Ahuja; J P Issa; S Markowitz; J K Willson; S R Hamilton; K W Kinzler; M F Kane; R D Kolodner; B Vogelstein; T A Kunkel; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

8.  Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

Authors:  M L Veigl; L Kasturi; J Olechnowicz; A H Ma; J D Lutterbaugh; S Periyasamy; G M Li; J Drummond; P L Modrich; W D Sedwick; S D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

9.  Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.

Authors:  Gijs van Haaften; Gillian L Dalgliesh; Helen Davies; Lina Chen; Graham Bignell; Chris Greenman; Sarah Edkins; Claire Hardy; Sarah O'Meara; Jon Teague; Adam Butler; Jonathan Hinton; Calli Latimer; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Jennifer Cole; Simon Forbes; Mingming Jia; David Jones; Chai Yin Kok; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maquire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Erin Pleasance; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Rachel Turner; Kelly Turrell; Jennifer Varian; Sofie West; Sara Widaa; Paul Wray; V Peter Collins; Koichi Ichimura; Simon Law; John Wong; Siu Tsan Yuen; Suet Yi Leung; Giovanni Tonon; Ronald A DePinho; Yu-Tzu Tai; Kenneth C Anderson; Richard J Kahnoski; Aaron Massie; Sok Kean Khoo; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nat Genet       Date:  2009-03-29       Impact factor: 38.330

10.  Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.

Authors:  Xiaying Chen; Zuyi Yang; Jiao Feng; Ting Duan; Ting Pan; Lili Yan; Ting Jin; Yu Xiang; Mingming Zhang; Peng Chen; Wengang Wang; Ruonan Zhang; Bi Chen; Liping Zhao; Tian Xie; Xinbing Sui
Journal:  Cancer Med       Date:  2020-11-11       Impact factor: 4.452

View more
  3 in total

1.  Cancer treatment-related financial toxicity experienced by patients in low- and middle-income countries: a scoping review.

Authors:  Suji Udayakumar; Eden Solomon; Wanrudee Isaranuwatchai; Danielle L Rodin; Yoo-Joung Ko; Kelvin K W Chan; Ambica Parmar
Journal:  Support Care Cancer       Date:  2022-03-23       Impact factor: 3.603

Review 2.  DNA Damage Repair in Brain Tumor Immunotherapy.

Authors:  Shihong Zhao; Boya Xu; Wenbin Ma; Hao Chen; Chuanlu Jiang; Jinquan Cai; Xiangqi Meng
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

3.  Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.

Authors:  Xiaying Chen; Zuyi Yang; Jiao Feng; Ting Duan; Ting Pan; Lili Yan; Ting Jin; Yu Xiang; Mingming Zhang; Peng Chen; Wengang Wang; Ruonan Zhang; Bi Chen; Liping Zhao; Tian Xie; Xinbing Sui
Journal:  Cancer Med       Date:  2020-11-11       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.